Navigation Links
XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome

SANTA CLARA, Calif.--(BUSINESS WIRE)--Apr 25, 2007 - XenoPort, Inc. (Nasdaq: XNPT) today announced top-line results from a Phase 3 clinical trial of XP13512 for the treatment of symptoms of primary restless legs syndrome (RLS). XP13512 demonstrated statistically significant improvements compared to placebo on both of the co-primary endpoints of the trial and was well tolerated.

"These results are very encouraging and represent a major advance for XenoPort, its partners and, potentially, RLS patients," said Ronald W. Barrett, Ph.D., chief executive officer of XenoPort.

This XenoPort study was a 12-week, double-blind, placebo-controlled Phase 3 clinical trial that enrolled 222 patients who were diagnosed with moderate-to-severe primary RLS. Patients were treated with either 1200 mg of XP13512 or placebo, given once per day. The co-primary endpoints for the clinical trial were the change from baseline for the International RLS (IRLS) rating scale score at end of treatment and the percentage of patients showing significant improvement on the Clinical Global Impression of Improvement (CGI-I) scale at end of treatment.

Treatment with 1200 mg of XP13512 was associated with a statistically significant improvement in the co-primary endpoints compared to placebo. Improvements in the IRLS Scale were significantly greater for XP13512 than for placebo (-13.2 vs. -8.8: p=0.0002). At the end of treatment, significantly more patients treated with XP13512 were reported as "much improved" or "very much improved" on the CGI-I scale compared to those treated with placebo (76% vs. 39%: p less than 0.0001).

During treatment over the 12-week period, the most commonly reported adverse events for XP13512 versus placebo were somnolence (26.5% XP13512; 7.4% placebo) and dizziness (19.5% XP13512; 4.6% placebo). There were no reported serious adverse events in XP13512-treated patients.

Dr. Barrett stated, "XP135
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/10/2014)... -- Integrated Silicon Solution, Inc. (Nasdaq: ISSI ... solutions, today announced that it will host its earnings ... a.m. Pacific Time (10:00 a.m. Eastern Time) to discuss ... quarter ended June 30, 2014. To access ... a.m. Pacific time on July 24, 2014.  The participant ...
(Date:7/10/2014)... TUCSON, Ariz. , July 10, 2014   ... Roche  Group, today announced it has entered into an ... , which operates as EMD Serono in ... , to collaborate with Merck KGaA,s biopharmaceutical division ... (CDx) for an undisclosed target using Ventana,s proprietary diagnostic ...
(Date:1/15/2014)... 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced sales ... compared to sales of $2,202,000 for the prior year period, ... has also shown growth over the preceding quarter,s sales, continuing ... fiscal year. Markets that experienced sales increases over the prior ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... (Nasdaq: BIOD ) announced today the appointment of ... is chairman of ArcherGroup, a private investment and consulting services ... newly-formed Kroll Bond Rating Agency.  He is a retired chairman ...  He spent 30 years at Merrill Lynch & Company where ...
... VIEW, Calif., Sept. 16 Based on its recent ... market, Frost & Sullivan recognizes Accelrys, Inc., with the ... Product Innovation of the Year. The company has merited ... a solution that provides, for the first time, a ...
Cached Medicine Technology:Biodel Appoints Arthur Urciuoli to its Board of Directors 2Biodel Appoints Arthur Urciuoli to its Board of Directors 3Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution 2Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution 3Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution 4
(Date:7/12/2014)... The Passenger Information System market is estimated ... million by 2019, at an expected CAGR of 26.5% ... public transport infrastructure in North America is well developed ... every corner of the region. The growing ridership figures ... service providers are driving the North American Passenger Information ...
(Date:7/12/2014)... The rise in the number of mobility devices ... architectures to suit the upsurge. Virtualization has become a ... storage technologies. The data traffic has increased by several ... has resulted in larger and more complex networks. These ... SDN market. , The North American (NA) region is ...
(Date:7/12/2014)... HealthDay Reporter SATURDAY, July 12, 2014 ... surgical technique used to grind up uterine growths and remove ... cancer to other parts of a woman,s body, U.S. health ... and Drug Administration also said that women who do undergo ... a written consent stating that they understand the potential risks, ...
(Date:7/12/2014)... 12, 2014 In this ... ‘cognitive assessment and training’ is defined as ... train, or enhance cognitive functions. These solutions ... in dementia screening, clinical trials, driver’s safety, ... self assessment, brain training, and employers’ assessment ...
(Date:7/12/2014)... 12, 2014 The Security Analytics market ... to $3,376.6 million by 2019, at an expected CAGR ... The challenges to counter the increasing number of security ... outdated cyber defense systems in organizations are enormous. Vendors ... remodeling their existing architecture to develop better and more ...
Breaking Medicine News(10 mins):Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4
... , WEDNESDAY, Feb. 2 (HealthDay News) -- Electrical ... insight that can help people solve new, difficult problems, ... who received electrical stimulation of the brain,s anterior temporal ... to figure out a challenging, unfamiliar problem than participants ...
... , WEDNESDAY, Feb. 2 (HealthDay News) -- A mother,s history ... only having a stroke but also her chances of having ... shows that stroke in mothers is associated with heart attacks ... at the Stroke Prevention Research Unit at the University of ...
... in the United States, account for a disproportionate share ... more than half of clinical trials exclude people based ... new study by Robert Wood Johnson Foundation (RWJF) Clinical ... findings are concerning because it means that doctors cannot ...
... a healthy response in reaction to potentially harmful presences ... lungs and builds up to a full-fledged asthma attack, ... directly associated with heart disease and other physical ailments. ... Biological Sciences Marcia Newcomer, together with Associate Professor Sue ...
... Chicago (February 02, 2011) The International Serious ... collaboration with the HMO Research Network (HMORN) to ... that may help predict risk associated with a ... collaboration will diversify the iSAEC methods for developing ...
... The adaptor protein thought to be active in killing cells ... that the presence of RIP1 is actually necessary for survival ... trigger, and the potential for developing new treatments for sepsis ... have identified a protein that plays a dual role in ...
Cached Medicine News:Health News:If Mom Had a Stroke, Daughter May Be Prone to Heart Attack 2Health News:If Mom Had a Stroke, Daughter May Be Prone to Heart Attack 3Health News:Older adults often excluded from clinical trials 2Health News:Breathing easy: LSU biochemists offer first 3-D model of asthma-causing inflammation enzyme 2Health News:iSAEC and HMORN to use electronic medical records to research genetics of drug-induced SAEs 2Health News:The 'death switch' in sepsis also promotes survival 2